COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics
CMPS Price/Volume Stats
| Current price | $6.63 | 52-week high | $12.75 |
| Prev. close | $6.72 | 52-week low | $5.01 |
| Day low | $6.35 | Volume | 725,100 |
| Day high | $6.78 | Avg. volume | 558,611 |
| 50-day MA | $7.04 | Dividend yield | N/A |
| 200-day MA | $8.24 | Market Cap | 453.37M |
CMPS Stock Price Chart Interactive Chart >
COMPASS Pathways PLC ADR (CMPS) Company Bio
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorderInitial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditionsLONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that an initial data readout showed that investigational COMP360 psilocybin treatment was well-tolerated in a phase 2 clinical trial of people living with post-tr |
25 Best Online Psychology Degree Programs Heading Into 2024In this article, we will be looking at the 25 best online psychology degree programs heading into 2024. If you want to skip our detailed analysis, you can go directly to the 5 Best Online Psychology Degree Programs Heading Into 2024. Global Mental Health Industry: An Overview According to a report by IMARC, the global mental health […] |
Compass Pathways appoints Teri Loxam as Chief Financial OfficerLONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company’s New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. Teri brings to Compass deep and |
Study results of psilocybin treatment in bipolar II depression published in JAMA PsychiatryBelieved to be first ever psilocybin clinical trial for treatment of bipolar II depressionLONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper inJAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Res |
Investing in Mental Health: 3 Stocks in the Wellness SpaceMental health stocks can be a great addition to your portfolio as its importance becomes increasingly recognized. |
CMPS Price Returns
| 1-mo | -5.29% |
| 3-mo | -4.47% |
| 6-mo | -37.86% |
| 1-year | -29.84% |
| 3-year | -80.19% |
| 5-year | N/A |
| YTD | -24.23% |
| 2023 | 8.97% |
| 2022 | -63.67% |
| 2021 | -53.61% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...